← Markets

Incyte Corporation

INCY · NASDAQ

Market closed$117.25$0.600000 (+0.51%)After hours $119.13 · +1.61%

Key statistics

Previous close$116.65
Open$116.75
Day high$119.60
Day low$116.27
52-week high$119.60
52-week low$67.17
Market cap23.42B
Volume2.19M
Average volume1.73M
P/E ratio15.76
Forward P/E—
EPS7.44
Dividend yield0.00%

Market context

Why it moved

Incyte shares edged higher after the company announced it will present Phase 1 oncology pipeline data, including a KRAS G12D inhibitor and a TGFβR2×PD-1 bispecific antibody, at the upcoming ESMO Congress 2026, reinforcing investor confidence in its pipeline depth alongside steady Jakafi revenue growth.

MarketsAd Hoc NewsAfpStocktitanStocktitan

What is happening

Recent company-specific developments and publisher coverage.

July 18, 2026Incyte closed modestly higher, touching its 52-week high of $119.60 intraday and continuing to gain in after-hours trading, as investors position ahead of its Q2 2026 earnings report due July 28. Analysts expect EPS of $1.61, up ~23% year-over-year, building on a strong Q1 beat driven by Jakafi and Opzelura growth. The stock now trades above the median analyst price target of $105, reflecting the 68%+ 52-week rally, while broader healthcare sentiment has improved per UBS, which cited biotech M&A tailwinds and stabilizing fundamentals as key catalysts.

0.5144

July 17, 2026Incyte closed modestly higher, approaching its 52-week high of $118.97, as investors look ahead to its Q2 2026 earnings report due July 28 and weigh mixed analyst sentiment. The stock has gained over 21% since its strong Q1 beat, with Q2 EPS consensus at $1.61 (+23% YoY), though analysts remain divided — price targets range from $94 (BMO Capital) to $140 (HC Wainwright) with a median of $105, meaning INCY now trades above the median target. Positive pipeline momentum from Phase 1/2 data for latarcibart showing 81% median bleeding reduction in VWD patients adds a potential catalyst, while UBS has flagged healthcare and biotech as a key sector allocation amid improving earnings revisions.

1.3555

July 16, 2026Incyte closed essentially flat as investors weigh a mixed fundamental picture: BofA Securities raised its price target to $136 from $124, while analysts remain divided on whether the stock is a buy, sell, or hold following Q1 earnings that beat EPS estimates but disappointed on full-year revenue guidance. Separately, strong Phase 1/2 data for latarcibart—showing an 81% median reduction in annualized bleeding rates in von Willebrand disease—presented at ISTH 2026 bolstered pipeline optimism, even as INCY trades lower in after-hours, down roughly 1.3%.

0.1828

July 15, 2026Incyte closed modestly higher, bolstered by a Barclays analyst upgrade raising its price target from $117 to $134 while maintaining an Overweight rating — a meaningful vote of confidence that pushed the target well above consensus. The bullish note coincides with encouraging pipeline momentum: Incyte recently presented Phase 1/2 data at ISTH 2026 showing its VWD candidate latarcibart delivered an 81% median reduction in annualized bleeding rate, with its pivotal Phase 3 VIVID-6 trial now enrolling. In after-hours trading, shares slipped modestly alongside broader healthcare softness.

0.569

July 14, 2026Incyte declined despite presenting promising Phase 1/2 data for latarcibart (VGA039) at ISTH 2026, showing an 81% median reduction in annualized bleeding rates across all von Willebrand disease types — a result that could position it as the first targeted therapy for VWD. Analyst sentiment remained cautious, with BMO Capital raising its price target to $112 (from $94) but maintaining Market Perform, while Jefferies also nudged its target to $105 with a Hold, suggesting the strong clinical data may not yet bridge the gap to a more constructive rating. Broader market headwinds from renewed U.S.-Iran tensions and a risk-off tone also weighed on healthcare shares.

-2.1249

July 11, 2026Incyte Corporation closed modestly lower, pulling back from its recent 52-week high, as mixed analyst sentiment and a minor EU regulatory nuance weighed on investor outlook. RBC Capital recently raised its price target to $99 but maintained a cautious 'Sector Perform' rating — well below current trading levels — while a SimplyWallSt analysis questioned whether Opzelura's EU label scope and Incyte's exit from several Russell growth indexes reframe the bull case. Still, key catalysts remain intact: the $1.25B acquisition of Vega Therapeutics (VGA039 in Phase 3 for von Willebrand disease) expands the hematology pipeline, and Q2 2026 earnings are due July 28, with positive market expectations. The broader biotech sector is experiencing renewed momentum, with XLV at record highs.

-1.5272

July 10, 2026Incyte closed modestly higher, touching a new 52-week high intraday at $118.97, buoyed by a confluence of positive catalysts. The company completed its $1.25 billion acquisition of Vega Therapeutics, adding VGA039 — a Phase 3 monoclonal antibody for von Willebrand disease — to its hematology pipeline, while the European Medicines Agency backed an expanded label for Opzelura in moderate atopic dermatitis. Investors are also looking ahead to Q2 2026 earnings on July 28, with the broader healthcare sector continuing its recent outperformance as biotech M&A sentiment remains buoyant.

1.0745

July 9, 2026Incyte closed modestly lower amid a broad market risk-off session triggered by renewed U.S.-Iran tensions, though the stock remained near its 52-week high and recovered slightly in after-hours trading. The company's recent completion of its $1.25 billion acquisition of Vega Therapeutics — adding VGA039, a Phase 3 monoclonal antibody for von Willebrand disease, to its hematology portfolio — has bolstered investor confidence, while the broader biotech sector continues to benefit from a notable rotation out of semiconductors, favorable M&A sentiment, and healthcare's recent run as the S&P 500's top-performing sector. Incyte also holds a "Strong Bullish" rating and has Q2 earnings scheduled for July 28.

-0.6692

Seeking Alpha · July 17, 2026Incyte: Profitable Biotech That Could Be Close To Exploding (NASDAQ:INCY)www.marketscreener.com · July 17, 2026Incyte Data to Be Highlighted in Four Rapid Oral Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 Support Efforts to Improve Outcomes in Difficult-to-Treat CancersSimply Wall Street · July 17, 2026Incyte (INCY) Reports Promising Latarcibart Data As Global Phase 3 BeginsMoomoo · July 15, 2026BofA Securities Maintains Incyte(INCY.US) With Buy Rating, Raises Target Price to $136Business Wire · July 8, 2026Incyte to Report Second Quarter Financial ResultsQuiver Quantitative · June 15, 2026Incyte slides as investors digest updated INCA033989 (mutCALR) data and a cautious analyst takeStock Titan · June 14, 2026FOP trial drug cuts new HO lesions 99.9%, gets FDA Priority ReviewSeeking Alpha · March 23, 2026Incyte: An Undervalued Healthcare Gem (NASDAQ:INCY)
Benzinga · July 17, 2026Incyte To Present New Phase 1 Solid Tumor Data, Including KRAS G12D and TGFβR2×PD‑1 Programs, At ESMO 2026
Mt Newswire · July 15, 2026BofA Securities Raises Incyte Price Target to $136 From $124
Mt Newswire · July 14, 2026Barclays Adjusts Incyte Price Target to $134 From $117, Maintains Overweight Rating
Benzinga · July 14, 2026Barclays Maintains Overweight on Incyte, Raises Price Target to $134
Mt Newswire · July 13, 2026BMO Capital Adjusts Price Target on Incyte to $112 From $94, Maintains Market Perform Rating
Benzinga · July 13, 2026Incyte Says Early Data Points To Promise For Once-Monthly Preventive Treatment For Inherited Blood Disorder
Mt Newswire · July 13, 2026Jefferies Adjusts Price Target on Incyte to $105 From $100, Maintains Hold Rating
Benzinga · July 13, 2026BMO Capital Maintains Market Perform on Incyte, Raises Price Target to $112

Peers

S&P 500SPX · $7,457.69-1.01%AbbVie Inc.ABBV · $254.49+0.04%Bristol-Myers Squibb CompanyBMY · $60.74+0.38%Novartis AGNVS · $153.76+0.67%Eli Lilly and CompanyLLY · $1,179.09+0.85%Pfizer Inc.PFE · $25.05-0.36%Regeneron Pharmaceuticals, Inc.REGN · $676.69-0.33%Alnylam Pharmaceuticals, Inc.ALNY · $267.47-5.54%Biogen Inc.BIIB · $205.99-1.40%Neurocrine Biosciences, Inc.NBIX · $170.88-0.39%Genmab A/SGMAB · $28.72-0.90%United Therapeutics CorporationUTHR · $535.67+1.25%